False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Abstract
Purpose: Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but assay accuracy has been debated. Because most cfDNA is derived from peripheral blood cells (PBC), we hypothesized that nonmalignant mutations harbored by hematopoietic cells (clonal hematopoiesis, CH) could be a cause of false-positive plasma genotyping.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 14, 2018
- Source ID
- 10.1158/1078-0432.ccr-18-0143
Entities
People
- Bryan C. Ulrich
- Cloud P. Paweletz
- Geoffrey R. Oxnard
- Julianna Supplee
- Kwok-kin Wong
- Mark M. Awad
- Nicolas M. Guibert
- Nora B. Feeney
- Pasi A. Janne
- Patrick H Lizotte
- Yanan Kuang
- Yuebi Hu
Organizations
- Damon Runyon Cancer Research Foundation
- Dana–Farber Cancer Institute
- National Cancer Institute
- United States Department of Defense